| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 06/14/2006 | EP1667725A2 Design of re-targeted toxin conjugates |
| 06/14/2006 | EP1667724A2 Albumin-binding derivatives of therapeutic peptides |
| 06/14/2006 | EP1667716A1 Cytotoxicity mediation of cells evidencing surface expression of cd44 |
| 06/14/2006 | EP1667709A1 Clostridium botulinum c3 exotransferase compositions and methods for treating tumour spreading |
| 06/14/2006 | EP1667708A2 Polymer conjugates of interferon- beta with enhanced biological potency |
| 06/14/2006 | EP1667704A1 Multiple-arm peptide compounds, methods of manufacture and use in therapy |
| 06/14/2006 | EP1667696A1 Probiotic storage and delivery |
| 06/14/2006 | EP1667672A1 Method for preventing and/or treating neurodegenerative diseases |
| 06/14/2006 | EP1667660A2 Pantoprazole multiparticulate formulations |
| 06/14/2006 | EP1667658A2 Granular sustained release preparation and production thereof |
| 06/14/2006 | EP1667656A1 Compositions and methods for delivery of biologically active agents |
| 06/14/2006 | EP1667655A1 New use, pharmaceutical preparations as well as a process for their production |
| 06/14/2006 | EP1667654A2 Methods for the controlled delivery of pharmacologically active compounds |
| 06/14/2006 | EP1667650A1 Skin care topical ointment |
| 06/14/2006 | EP1667648A2 Compositions and methods for treating burns |
| 06/14/2006 | EP1667633A2 Polysaccharides for pulmonary delivery of active agents |
| 06/14/2006 | EP1667522A2 Modified oligonucleotides for telomerase inhibition |
| 06/14/2006 | EP1496951B1 Wound dressings comprising an oxidoreductase enzyme in hydrated condition |
| 06/14/2006 | EP1487514B1 Deposition method for endoprostheses provided for constantly administering medicaments |
| 06/14/2006 | EP1476136B1 Pharmaceutical composition comprising n-((1-n-butyl-4-piperidinyl)menthyl)-3,4-dihydro-2h-(1,3)oxazino(3,2-a)indole-10-carboxamide or salt and process for preparing thereof comprising dry granulation |
| 06/14/2006 | EP1438076B1 Radiopharmaceutical agent for the treatment of early stage cancer |
| 06/14/2006 | EP1404353A4 Methods of using a hyaluronan receptor |
| 06/14/2006 | EP1401500A4 Nucleotide compounds that block the bitter taste of oral compositions |
| 06/14/2006 | EP1372693B1 Peptides for the treatment of wound contracture |
| 06/14/2006 | EP1313457B1 Transdermal therapeutic system for releasing venlafaxine |
| 06/14/2006 | EP1309315B1 Rapidly disintegrating oral formulation of valdecoxib |
| 06/14/2006 | EP1289475B1 Water-thin emulsions with low emulsifier levels |
| 06/14/2006 | EP1263771B1 Chemoselective ligation by use of a phosphine |
| 06/14/2006 | EP1261361B1 Oral, nasal and pulmonary dosage formulations of copolymer 1 (glatiramer acetate) |
| 06/14/2006 | EP1255558B1 Anti-april antibodies and hybridoma cells |
| 06/14/2006 | EP1180015B8 Generation of therapeutic microfoam |
| 06/14/2006 | EP1175205B1 Solid dispersion comprising ritonavir, fenofibrate or griseofulvin |
| 06/14/2006 | EP1143963B1 Multiparticulate bisoprolol formulation |
| 06/14/2006 | EP1102742B1 Compounds and compositions for delivering active agents |
| 06/14/2006 | EP1071468B1 Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor |
| 06/14/2006 | EP1069890B1 Incorporation of active substances in carrier matrixes |
| 06/14/2006 | EP1003551B1 Antigen delivery system comprising monoglyceride or diglyceride derivatives as adjuvant |
| 06/14/2006 | EP0934593B1 Electrically conductive adhesive hydrogels |
| 06/14/2006 | DE102005059420A1 Paste useful for treating dermatological diseases of the oral mucosa, contains a virustatic agent in an anhydrous base that adheres to the mucosa |
| 06/14/2006 | DE102004058952A1 Verfahren zur Herstellung wässriger Sekundärdispersionen von in Wasser nicht löslichen Polymeren A process for the preparation of aqueous secondary dispersions of water-insoluble polymers |
| 06/14/2006 | CN1787840A Drug for treating hemophilia and method of treating hemophilia using the same |
| 06/14/2006 | CN1787839A Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections |
| 06/14/2006 | CN1787838A Antitumor agents comprising a targeting portion and an immune response triggering portion |
| 06/14/2006 | CN1787833A Pharmaceutical preparations comprising acid-stabilised insulin |
| 06/14/2006 | CN1787824A External preparation for improving coital function |
| 06/14/2006 | CN1787810A Cladribine formulations for improved oral and transmucosal delivery |
| 06/14/2006 | CN1787809A Oral formulations of cladribine |
| 06/14/2006 | CN1787808A Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles |
| 06/14/2006 | CN1785972A Premedicine acting on nervous centralis system |
| 06/14/2006 | CN1785431A Adjuvant of slow release agent used for eye and medicine containing said adjurant and its preparation method |
| 06/14/2006 | CN1785430A Nano-magnetic powder antihuman lirer cancer single anti HAb18 target medicine for magnetic heat therapy |
| 06/14/2006 | CN1785425A Preparation method of poly peptide vaccine for treating lefteye flounder adenolymphocele |
| 06/14/2006 | CN1785203A Astragaloside cyclodextrin clathrate, its prepn. and preparing mehtod |
| 06/14/2006 | CN1785163A Immune effervescent tablets for drinking water and its prepn. method |
| 06/14/2006 | CN1259107C Composition of half solid framework preparation of ginkgo leaf extract product |
| 06/14/2006 | CN1259053C Medicinal preparation containing erythromycine ethylsuccinate |
| 06/14/2006 | CN1259052C Medicinal composition for treating burn and scald and preparing method |
| 06/14/2006 | CN1259003C Method for molecular press dehydration of vegetative tissue, dehydrated tissues and dehydrated exudates obtained and processing products containing same |
| 06/13/2006 | USRE39125 Swallowing-assistive drink |
| 06/13/2006 | US7060828 Angiogenosis inhibitor; anticancer agents |
| 06/13/2006 | US7060802 Monoclonal antibody hybridomas ; detecting cancer |
| 06/13/2006 | US7060732 Antiacne; skin disorders; packaged separately |
| 06/13/2006 | US7060724 Water soluble paclitaxel derivatives |
| 06/13/2006 | US7060708 Active agent delivery systems and methods for protecting and administering active agents |
| 06/13/2006 | US7060694 High potency dihydroergotamine compositions |
| 06/13/2006 | US7060689 Methods and compositions for delivery and retention of active agents to lymph nodes |
| 06/13/2006 | US7060675 Administering by mouth an effective amount of an insulin polypeptide derivative within one hour of ingestion of a meal by the patient to provide an insulin drug concentration in portal vein blood of 10-1,000 U/ml within 60 minutes |
| 06/13/2006 | US7060672 Cyclosporin analog formulations |
| 06/13/2006 | US7060498 Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers |
| 06/13/2006 | US7060307 Topical composition for heightened sensitivity |
| 06/13/2006 | US7060305 extracts contain higher concentration of isoflavones; used to treat erectile dysfunction or malfunction |
| 06/13/2006 | US7060298 Comprises biocompatible hydrophilic cationic microparticles and cell adhesion promoter implanted into the lower esophageal sphincter |
| 06/13/2006 | US7060297 Transitional viscoelastics (having non-shear related variable viscosities) contain kappa-carrageenans, potassium and second sulfated polysachharide for protecting or stabilizing eye tissues during surgery |
| 06/13/2006 | US7060296 Biodegradation, time-release agents, drug delivery |
| 06/13/2006 | US7060290 Phosphocholine linked prodrug derivatives |
| 06/13/2006 | US7060289 Topical glycopyrrolate product |
| 06/13/2006 | US7060285 Dispersions for the formulation of slightly or poorly soluble agents |
| 06/13/2006 | US7060284 Polypeptides and polynucleotides for enhancing immune reactivity to HER-2 protein |
| 06/13/2006 | US7060274 Receptor specific transepithelial transport of therapeutics |
| 06/13/2006 | US7060263 Super absorption Coenzyme Q10 |
| 06/13/2006 | US7060259 Hydrolytically degradable carbamate derivatives of poly(ethylene glycol) |
| 06/13/2006 | US7060255 Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route |
| 06/13/2006 | US7060254 Aerosol; heating thin film on solid support; vaporization with air flow |
| 06/13/2006 | US7060248 Chelate compounds; diagnosis of disease; detection of conjestive heart failurel |
| 06/13/2006 | CA2309836C Drug delivery systems utilizing liquid crystal structures |
| 06/08/2006 | WO2006060618A2 Topical nepafenac formulations |
| 06/08/2006 | WO2006060533A2 Conjugates of 1, 8-bis-naphthalimides with an antibody |
| 06/08/2006 | WO2006060464A1 Methods of using temozolomide formulation intrathecally in the treatment of cancers |
| 06/08/2006 | WO2006060044A1 Toxin compounds with enhanced membrane translocation characteristics |
| 06/08/2006 | WO2006059753A1 Novel oral pharmaceutical suspension of cefdinir crystal |
| 06/08/2006 | WO2006059716A1 Solid preparation |
| 06/08/2006 | WO2006059664A1 Stabilized inorganic nanoparticle, stabilized inorganic nanoparticles, process for producing stabilized inorganic nanoparticle, and method of utilizing stabilized inorganic nanoparticle |
| 06/08/2006 | WO2006059221A2 Topical hydro-alcoholic formulations of oxazolidinone antibacterial agents |
| 06/08/2006 | WO2006058671A1 Aqueous dispersions of a mixture of only slightly water soluble or water insoluble active substances and a single-celled protein material |
| 06/08/2006 | WO2006033948A3 Sustained local anesthetic composition containing preferably a sugar ester such as saib |
| 06/08/2006 | WO2006017347B1 Opthalmic compositions and methods for treating ophthalmic conditions |
| 06/08/2006 | WO2006002887A8 Aqueous drink solution of indibulin (d-24851) and an organic acid |
| 06/08/2006 | WO2005120563A3 Induction of an immune response against streptococcus pneumoniae polysaccharides |
| 06/08/2006 | WO2005116067A3 Msh-agonist tripeptide conjugates |
| 06/08/2006 | WO2005111224A3 Water-soluble coenzyme q10 in inclusion complex with beta-cyclodextrin, process of preparing, and use thereof |